Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Descovy safety no match for cost savings with generic Truvada, study says
Key clinical point: Economically, the modest safety benefit of Descovy for HIV preexposure prophylaxis won’t justify paying thousands of dollars more for it when Truvada becomes available as a generic in a year or so.
Major finding: The improved safety of Descovy is worth no more than an additional $370 per person per year.
Study details: Cost-effectiveness analysis.
Disclosures: The work was funded by the National Institutes of Health and Massachusetts General Hospital. The investigators didn’t have any industry disclosures.
Citation:
Walensky RP et al. Ann Intern Med. 2020 Mar 10. doi:10.7326/M19-3478.